LDS/Medical Tests/Comprehensive Pharmacogenetics (PGx) Gene Variation Panel

Comprehensive Pharmacogenetics (PGx) Gene Variation Panel

Pharmacogenetic testing is used to predict the responses to medications of patients using their genetic information. It combines patient genetic, pharmacological information, along with the clinic to help prevent serious adverse drug reactions (ADR). The medication selection guide and dosing for patients is given by the interpretation of genotype. US Food and Drug Administration (FDA) has approved many drug labels to include some pharmacogenetic information. Dosing Guidelines for more than 70 drugs have been published by the Clinical Pharmacogenetics Implementation Consortium and/or Royal Dutch Association for the Advancement of Pharmacy. In order to test for patient genetic information, an increasing number of pharmacogenetic tests are being developed as FDA-approved diagnostic tests. However, all in vitro pharmacogenetic tests are based on single gene or for single drug test. To get a comprehensive assessment and a more thorough understanding of patient genetic information, it will be necessary to test a combination of related genes that affect the patient medication.

Depending on laboratory panel design and patient population, Comprehensive Pharmacogenetics testing panel should include most relevant and most common genes covering more than 90% of the drugs utilized for patient care. Genes included in this panel are as follow: ABCB1, ABCG2, ADRA2A, ADRB2, ANKK1, COMT, CYP1A2, CYP1B1, CYP2B6, CYP2C19, CYP2C8, CYP2C9, CYP2D6, CYP3A4, CYP3A5, CYP4F2, CYP6A2, DPYD, DRD2, EPHX1, GIRK4, HTR1A, HTR2A, HTR2C, ITGB3, MFFI, NUDT, OPMR1, SLCO1B1, TPMT, UGT, VKORC1.

In addition, this comprehensive panel will include genetic variation of coagulation factors FV, FII and MTHFR used for thrombotic genetic risk evaluation as well as APOE genetic variation for arteriosclerosis and cardiovascular disease risk assessment and Alzheimer’s disease risk assessment. The genetic variations (mutations) of the above listed genes are tested using PCR based TaqMan® genotyping assay that uses PCR amplification and allele specific probe (ARMS) for mutation detection.

  • Evaluation of drug therapy used for chronic diseases and disorders (long term therapy use) such as cardiovascular, psychotropic or mental illness, oncology and pain management
  • Therapy selection and monitoring for chronic diseases and disorders (long term therapy use) such as cardiovascular, psychotropic or mental illness, oncology and pain management
Poor Metabolizer: Increased efficacy of active drug; active metabolite may accumulate; usually require lower dose to avoid toxic accumulation. Decreased efficacy of prodrug; prodrug may require lower dose to avoid toxic accumulation or require an alternate drug. Ultra-Rapid Metabolizer: Decreased efficacy of active drug; active metabolite rapidly inactivated usually require higher dose to offset inactivation. Increased efficacy of prodrug; rapid onset of effect, may require lower dose to prevent excessive accumulation of active metabolite. A Strong inhibitor is one that causes a > 5-fold increase in the plasma AUC values or more than 80% decrease in clearance A Moderate inhibitor is one that causes a > 2-fold increase in the plasma AUC values or 50-80% decrease in clearance. A Weak inhibitor is one that causes a > 1.25-fold but < 2-fold increase in the plasma AUC values or 20-50% decrease in clearance.

See individual assay.

Polymerase chain reaction (PCR) and allele-specific primer extension, next generation sequencing (NGS).

Whole blood (EDTA), buccal swab, saliva.

Stability

  • Ambient: 3-5 days
  • Refrigerated: 7-14 days
Drugs screening and drug confirmation.
3-7 days.
Please log in to view content.
Create an account to get a 30-day free trial.
Login
Please log in to view content.
Create an account to get a 30-day free trial.
Login
Please log in to view content.
Create an account to get a 30-day free trial.
Login